Keyphrases
Polymyxin
100%
Intraventricular
100%
Intrathecal
100%
Systems-based Approach
100%
Pharmacology
100%
CNS Infection
66%
Superbugs
33%
Pharmacokinetics-pharmacodynamics (PK-PD)
33%
Systems Pharmacology
33%
Infection Model
22%
Gram-negative
22%
New Antibiotics
22%
Neurotoxicity
22%
Pseudomonas Aeruginosa Pneumonia
11%
Polymyxin B
11%
Dosing Recommendations
11%
Nephrotoxicity
11%
Klebsiellapneumoniae
11%
Infectious Diseases Society of America
11%
Antibiotic Combination
11%
CSF Pharmacokinetics
11%
Colistin
11%
Antibiotic pipeline
11%
Multidrug-resistant Gram-negative Bacteria
11%
Edge System
11%
Carbapenem-resistant Acinetobacter Baumannii
11%
Catastrophic Expenditure
11%
Klebsiella Pneumoniae (K. pneumoniae)
11%
Baumannii
11%
Clinical Utility
11%
Toxicity Data
11%
Nervous System
11%
CNS Tissue
11%
High Mortality Rate
11%
Last Line
11%
Specific Intent
11%
Pseudomonas Aeruginosa (P. aeruginosa)
11%
Dosage Regimen
11%
Edge Imaging
11%
Life-threatening
11%
Antibiotics
11%
Neuronal Cells
11%
Hit List
11%
First-ever
11%
Pharmacokinetic-pharmacodynamic Modeling
11%
Clinical Practice
11%
Mechanism-based
11%
Multidisciplinary Projects
11%
Pharmacology, Toxicology and Pharmaceutical Science
Polymyxin
100%
Intrathecal
100%
Central Nervous System Infection
66%
Pharmacokinetics
55%
Antibiotics
44%
Pharmacodynamics
33%
Infectious Agent
22%
Neurotoxicity
22%
Pseudomonas aeruginosa
22%
Multidrug-Resistant Gram-Negative Bacteria
11%
Polymyxin B
11%
Colistimethate
11%
Pharmacodynamic Modeling
11%
Nephrotoxicity
11%
Mortality Rate
11%
Acinetobacter Baumannii
11%
Diseases
11%